Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01693601 · ClinicalTrials.gov registry record · Phase 1
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
A Phase 1 study, sponsored by John Mascarenhas.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01693601 is a Phase 1 study that has completed, run by John Mascarenhas. The registered enrollment target is 15 participants.
The verdict
NCT01693601, a Phase 1 study, has completed, sponsored by John Mascarenhas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.
Interventions
- DRUG Ruxolitinib
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-01 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01693601
The ClinicalTrials.gov registry entry for NCT01693601 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Mascarenhas, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT01693601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01693601 about?
NCT01693601 is a clinical study titled "Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)". This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.
What is the current status of trial NCT01693601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-01. Estimated completion is 2018-05-18.
What interventions are being tested in trial NCT01693601?
The interventions under investigation include: Ruxolitinib (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT01693601?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.